Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap
If 2017 ended today, Aurinia Pharmaceuticals (NASDAQ: AUPH) would rank as one of the biggest winners of the year among biopharmaceutical stocks. Aurinia's share price has more than tripled so far this year.
Is Aurinia overpriced after such tremendous gains? Some might think so. The stock has basically treaded water over the past six months after starting off the year with a roar. However, Aurinia stock is still dirt cheap, in my view, for a couple of key reasons.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Aktie
43,94 €
-2,27 %
Die Community zeigt leichtes Interesse an Bristol-Myers Squibb mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 65 € für Bristol-Myers Squibb impliziert eine deutliche Steigerung um über 20% gegenüber 43.94 €.
